Beijing’s BioMap, an AI Drug Discovery Startup, Signs $1 Billion Deal with Sanofi

BioMap, a three-year old Beijing AI drug discovery company, formed a strategic collaboration with France’s Sanofi to co-develop new protein therapies in a deal with potential value of more than $1 billion. Unlike previous drug AI companies that are based on labeled data, BioMap’s AI models enable one large model, trained on ubiquitous unlabeled data, to build multiple downstream task models. The company believes its approach offers superior prediction from limited data across a range of therapeutic areas. BioMap was founded by Robin Li and Wei Liu, who previously founded Baidu, the Beijing-based internet search and AI company. More details....

Share this with colleagues: